Corvus Pharmaceuticals Inc (CRVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $897.52M
Last updated: Nov 17, 2026 at 4:43 PM ET
Corvus Pharmaceuticals Inc (CRVS) Stock Chart
Corvus Pharmaceuticals (CRVS) has a latest price of $10.17 on Nov 17, 2026, 62.3% below its 52-week high of $26.95. Its price rose 16.0% over the past 12 months. The month-end price fell 24.9% over the 10 years through Oct 2026, a compound annual decline of 2.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $20.77 in Mar 2017 and its lowest $0.73 in Feb 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CRVS with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CRVS.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 34.0%, and over 6 months it fell 11.6%. The month-end price rose 787.6% over the 3 years through Oct 2026, a compound annual rate of 107.0%.
| Period | Change |
|---|---|
| 1 month | +5.4% |
| 3 months | -34.0% |
| 6 months | -11.6% |
| 12 months | +16.0% |
| 12 months, with dividends | +16.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +787.6% | +107.0% |
| 5 years | +121.4% | +17.2% |
| 10 years | -24.9% | -2.8% |
Price by Year
Its best calendar year was 2024, when the price rose 204.0%, and its weakest was 2022, when it fell 64.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $10.03 | +30.3% |
| 2025 | $7.70 | +43.9% |
| 2024 | $5.35 | +204.0% |
| 2023 | $1.76 | +107.1% |
| 2022 | $0.85 | -64.7% |
| 2021 | $2.41 | -32.3% |
| 2020 | $3.56 | -34.6% |
| 2019 | $5.44 | +48.2% |
| 2018 | $3.67 | -64.6% |
| 2017 | $10.36 | -27.6% |
Trading Range
The price is 7.8% below its 50-day average of $11.03 and 26.8% below its 200-day average of $13.89.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $10.17 | |
| 52-week high | $26.95 | -62.3% |
| 52-week low | $6.39 | +59.2% |
| 50-day average | $11.03 | -7.8% |
| 200-day average | $13.89 | -26.8% |
Price Risk
Over 3 years, its largest fall from a peak was 70.5%.
| Measure | Value |
|---|---|
| 1-year beta | 0.67 |
| Largest fall, 1 year | -63.2% |
| Largest fall, 3 years | -70.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CRVS
What is CRVS's 1-year price change?
Corvus Pharmaceuticals's price rose 16.0% over the past 12 months. With dividends included, the 12-month total return was 16.0%.
What is CRVS's 5-year price change?
Corvus Pharmaceuticals's month-end price rose 121.4% over the 5 years through Oct 2026, a compound annual rate of 17.2%. These figures leave out dividends.
What is CRVS's 52-week high and low?
Corvus Pharmaceuticals's 52-week high is $26.95 and its 52-week low is $6.39. Its latest price of $10.17 on Nov 17, 2026 is 62.3% below the high.
What is CRVS's beta?
Corvus Pharmaceuticals's 1-year beta against the S&P 500 is 0.67, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 63.2%.
Is the CRVS chart free?
Yes. Advanced Charting for CRVS is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CRVS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors